Large Volume Parenteral (LVP) Market Report 2025

The large volume parenteral (LVP) market size has grown strongly in recent years. It will grow from $12.52 billion in 2024 to $13.57 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, growth in the aging population, rising demand for sterile pharmaceuticals, expansion of healthcare infrastructure, and development of regulatory frameworks for pharmaceuticals.

The large volume parenteral (LVP) market size is expected to see strong growth in the next few years. It will grow to $19.46 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to growing demand for biologics and biosimilars, rising healthcare expenditure, expansion of pharmaceutical outsourcing, increasing focus on personalized medicine, and globalization of pharmaceutical supply chains. Major trends in the forecast period include technological advancements in manufacturing processes, integration of advanced technologies in pharmaceutical production, implementation of single-use technologies, development of high-concentration formulations, and rise in 3d printing applications for pharmaceuticals.

The increasing prevalence of chronic diseases is expected to drive the growth of the large-volume parenteral market in the coming years. Chronic diseases are defined as illnesses or conditions that typically persist for three months or longer and can worsen over time. The rise in chronic diseases is largely attributed to factors such as tobacco use, exposure to secondhand smoke, and poor nutrition. Patients with chronic conditions often require a precise balance of essential nutrients to maintain their strength, and parenteral administration allows for the accurate delivery of pharmaceutical dosages, as most of the drug is directly absorbed into circulation, bypassing the digestive system. For example, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that there are 41 million deaths annually worldwide, representing 74% of fatalities caused by non-communicable diseases (NCDs) or chronic diseases. Therefore, the growing prevalence of chronic diseases is driving the expansion of the large-volume parenteral market.

The rising healthcare expenditure is expected to drive the growth of the large-volume parenteral (LVP) market in the future. Healthcare expenditure refers to the increasing amount of money allocated for healthcare services and related activities, including health research and public health initiatives. Higher healthcare spending is often linked to the development and expansion of healthcare infrastructure, such as the construction of new hospitals, clinics, and healthcare facilities. Improved infrastructure enhances the capacity to deliver medical services, thereby increasing the demand for LVP solutions. For example, in 2022, the Office for National Statistics, a UK-based national statistics organization, reported that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to 2021. Thus, the increasing healthcare expenditure is driving the growth of the large-volume parenteral market.

Product innovation is a prominent and popular trend in the large-volume parenteral market, with major players dedicating efforts to the creation of innovative products to enhance their market positions. An illustrative example of this trend is observed with SGD Pharma SA, a France-based producer of molded and tubular glass for pharmaceutical primary packaging. In March 2022, SGD Pharma launched 100-ml type I molded glass vials that are sterile and ready for aseptic filling and finishing of parenteral medicinal formulations. These vials serve to prevent scratches, facilitate the visual examination of filled vials, and reduce the likelihood of rejection during quality control processes. This product innovation aligns with the market's focus on enhancing the quality and efficiency of large-volume parenteral products.

Major players in the market are strategically focusing on the development of innovative formulations to bolster their market position. The creation of innovative formulations plays a pivotal role in driving the success and growth of the large volume parenteral market. These formulations address clinical challenges, enhance patient outcomes, and adapt to the dynamic landscape of healthcare. For instance, in November 2022, WuXi AppTec, a leading pharmaceutical development and manufacturing company based in China, launched a Parenteral Formulation Manufacturing Line in Wuxi City. This new line features an integrated 15 m³ lyophilizer housed in a completely enclosed isolator, along with a fully automated vial loading and unloading system. The filling line accommodates vials for solutions and lyophilized powder in various sizes, enabling quick mode transitions and significantly accelerating large-volume parenteral drug product production speed at 200 vials per minute. The facility boasts an innovative filling machine and a state-of-the-art containment system, aligning with global cGMP requirements.

In March 2022, Fresenius Kabi, a healthcare company based in Germany, made a strategic move by acquiring Ivenix Inc. for $240 million. This acquisition aims to broaden Fresenius Kabi's access to infusion systems in hospitals, complementing its intravenous fluids and infusion treatment offerings, and reinforcing its position in the US market. Ivenix Inc., a US-based medical technology company, specializes in the development of the Ivenix Large Volume Pump (LVP). This strategic acquisition further strengthens Fresenius Kabi's capabilities in the large volume parenteral market.

Major companies operating in the large volume parenteral (LVP) market include Pfizer Inc., Fresenius Kabi AG, Abbott Laboratories Inc., Becton Dickinson and Company, Otsuka Holdings Co Ltd., Baxter International Inc., B Braun Melsungen AG, Grifols SA, Cipla Limited, ICU Medical Inc., Biocon Limited, Sichuan Kelun Pharmaceutical Co. Ltd., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Gland Pharma Limited, Akums Drugs & Pharmaceuticals Ltd., Beximco Pharmaceutical Ltd., Nelson Laboratories LLC, Taj Pharmaceuticals Limited, Albert David Ltd., Amanta Healthcare Ltd., Unique Pharmaceutical Laboratories Ltd., Ahlcon Parenterals India Ltd, Parenteral Drugs Limited, Abaris Healthcare Pvt. Ltd., BML Parenteral Drugs, Denis Chem Lab Ltd, Pentagon Labs Ltd., DJ Labs Pvt Ltd., Higgs Healthcare.

North America was the largest region in the large volume parenteral (LVP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the large volume parenteral (lvp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the large volume parenteral (lvp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Large Volume Parenteral (LVP) pertains to sterile intravenous solutions with a volume of 100 ml or more, undergoing terminal sterilization through heat. These solutions play a crucial role in intravenous infusions, facilitating the administration of hydration, nourishment, and medications.

The primary types of Large Volume Parenteral (LVP) include soft bag LVP, plastic bag LVP, and glass bottle LVP. Soft bag LVP involves the use of flexible bags containing sterilized intravenous solutions, employed in medical settings to deliver fluids and medications to patients. The varying volumes, ranging from 100 ml to 2000 ml and beyond, cater to different infusion needs, such as basic infusion, therapeutic infusion, and nutritious infusion. End-users of LVP include hospitals, medical centers, and other healthcare facilities.

The large volume parenteral (LVP) market research report is one of a series of new reports that provides large volume parenteral (LVP) market statistics, including large volume parenteral (LVP) industry global market size, regional shares, competitors with a large volume parenteral (LVP) market share, detailed large volume parenteral (LVP) market segments, market trends and opportunities, and any further data you may need to thrive in the large volume parenteral (LVP) industry. This large volume parenteral (LVP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The large-volume parenteral (LVP) market consists of sales of sterile intravenous solutions, peritoneal dialysis solutions, plasma substitutes, and sterile powders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.